ClinicalTrials.gg
Active, not recruitingNCT07459127Updated Mar 9, 2026

Multicenter Retrospective Cohort of Pulmonary NUT Carcinoma

An observational study in NUT Carcinoma, sponsored by Three Gorges Hospital of Chongqing University. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Three Gorges Hospital of Chongqing University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Sex
All
01

Study summary

This study is a multi-center, retrospective observational study of patients with lung NUT carcinoma. Existing clinical records from participating hospitals will be reviewed to describe patient characteristics, treatments, and outcomes. No study-related interventions will be performed. Data will be de-identified to protect patient privacy.

Read the detailed description

This is a multi-center, retrospective observational cohort study of lung NUT carcinoma. Eligible patients diagnosed with lung NUT carcinoma at participating hospitals will be identified based on pathology with supportive evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion. Data will be extracted from existing medical records and follow-up documentation, including demographics, tumor characteristics, staging, treatments, and outcomes. When available, routine-care pathology information and imaging data will be collected and de-identified.

Primary outcome: progression-free survival (PFS).

Secondary outcomes: overall survival (OS) and other routinely documented outcomes when available.

No new drugs, devices, procedures, or additional tests will be provided as part of this research. All data will be de-identified and stored with access controls according to applicable regulations and ethics approvals at each participating site.

02

Conditions studied

  • NUT Carcinoma

Keywords

  • NUTM1
  • Pulmonary NUT carcinoma
  • Retrospective cohort
  • Multicenter
03

In context

Lead sponsor

Three Gorges Hospital of Chongqing University is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with pulmonary (lung) NUT carcinoma identified retrospectively from participating hospitals using pathology records, with clinical, pathologic, and imaging data abstracted from existing medical records and de-identified for analysis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed pulmonary (lung) NUT carcinoma.
  • Evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion, per local pathology report.
  • Diagnosed and/or treated at a participating hospital during the study period.
  • Availability of sufficient medical record data to abstract key baseline characteristics, treatments, and outcomes.

Exclusion criteria

Exclusion Criteria:

  • Primary tumor site not in the lung.
  • Records insufficient to confirm the diagnosis of pulmonary NUT carcinoma.
  • No follow-up or outcome information available after diagnosis (insufficient for survival/outcome assessment).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (actual)
Patient registry
No

Interventions

  • OtherStandard-of-care anticancer treatment (retrospective)

    Treatments received as part of routine clinical care and recorded retrospectively in medical records, which may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy. No study-related intervention will be assigned or provided. This observational study only collects and analyzes de-identified real-world treatment and outcome data.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time from initial diagnosis (index date) to first documented disease progression per routine clinical assessment or death from any cause, whichever occurs first.

    Time frame: From diagnosis through study completion (up to May 2026)

Secondary outcomes

  1. Overall Survival (OS)

    Time from initial diagnosis (index date) to death from any cause.

    Time frame: From diagnosis through study completion (up to May 2026)

07

Study locations

1 site
08

References and documents

Publications

  • Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Luer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, London WB, Sallan SE, Bradner JE, French CA. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012 Oct 15;18(20):5773-9. doi: 10.1158/1078-0432.CCR-12-1153. Epub 2012 Aug 15. PubMed 22896655 ↗
  • Kloker LD, Sidiras M, Flaadt T, Brecht IB, Deinzer CKW, Gross T, Benzler K, Zender L, Lauer UM. Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients. Lung Cancer. 2024 Mar;189:107496. doi: 10.1016/j.lungcan.2024.107496. Epub 2024 Jan 29. PubMed 38301600 ↗
  • Luo J, Bishop JA, DuBois SG, Hanna GJ, Sholl LM, Stelow EB, Thompson LDR, Shapiro GI, French CA. Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. Nat Rev Clin Oncol. 2025 Apr;22(4):292-306. doi: 10.1038/s41571-025-00986-3. Epub 2025 Feb 3. PubMed 39900969 ↗
  • Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R, Lathan CS, DuBois SG, Haddad RI, Shapiro GI, Sallan SE, Dhar A, Nelson JJ, French CA. An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz094. doi: 10.1093/jncics/pkz094. eCollection 2020 Apr. PubMed 32328562 ↗
  • Yuan J, Xu Z, Guo Y. Diagnosis, Treatment and Prognosis of Primary Pulmonary NUT Carcinoma: A Literature Review. Curr Oncol. 2022 Sep 22;29(10):6807-6815. doi: 10.3390/curroncol29100536. PubMed 36290813 ↗
  • Lemelle L, Flaadt T, Fresneau B, Moya-Plana A, Timmermann B, Roganovic J, Ferrari A, Fichera G, Lauer UM, Ben-Ami T, Schneider DT, Vokuhl C, Bolle S, Fox E, DuBois SG, Rodriguez-Galindo C, Bisogno G, Surun A, Brecht IB, Orbach D. NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations. J Pediatr Hematol Oncol. 2023 May 1;45(4):165-173. doi: 10.1097/MPH.0000000000002568. Epub 2022 Oct 10. PubMed 36219702 ↗
  • Luo W, Stevens TM, Stafford P, Miettinen M, Gatalica Z, Vranic S. NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review. Curr Oncol. 2021 Nov 7;28(6):4485-4503. doi: 10.3390/curroncol28060381. PubMed 34898574 ↗
  • Ye Z, Yan H, Li X, Yang D, Xie F, Deng C, Yin M. Radiotherapy Outcomes and Prognostic Factors in Head and Neck NUT Carcinoma: A Single-Center Cohort Analysis. Head Neck. 2026 Apr;48(4):975-985. doi: 10.1002/hed.70119. Epub 2025 Dec 2. PubMed 41328494 ↗
  • Ye Z, Li X, Xie F, Sun J, Yang D, Deng C, Yin M. A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma. Oral Oncol. 2025 Mar;162:107185. doi: 10.1016/j.oraloncology.2025.107185. Epub 2025 Jan 24. PubMed 39862476 ↗
  • Ye Z, Li X, Zhang M, Xie F, Luo X, Deng C, Yang D, Yin M. Complete Response to BET Inhibitor in Primary Pulmonary NUT Carcinoma With Single-Cell Sequencing-Based Analysis: A Case Report. JTO Clin Res Rep. 2025 Aug 5;6(10):100885. doi: 10.1016/j.jtocrr.2025.100885. eCollection 2025 Oct. PubMed 40926997 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Apr 2026, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 9, 2026
StartActual
Jan 1, 2023
Primary completionEst.
Apr 1, 2026
CompletionEst.
May 1, 2026
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07459127
Lead sponsor
Three Gorges Hospital of Chongqing University
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Jan 1, 2023
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Mar 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion